Recent approvals of Halozyme's drug delivery technologies in cancer treatments, highlighting significant clinical advancements in several diseases.
This month saw approvals for two products employing Halozyme's Enhanze drug delivery technology (BMS's Opdivo and Johnson and Johnson's DARZALEX FASPRO®). A number of collaborations between industry partners and charities to fight the disease, including Duchenne muscular dystrophy and Epidermolysis Bullosa, have been announced. Successful clinical trial data was disclosed for products employing a wide variety of therapeutic delivery technologies including Perfuse Therapeutics intravitreal implant for glaucoma, Aspen Neurosciences precision delivery of an autologous dopaminergic neuronal precursor cell therapy for Parkinson's disease and Resurge Therapeutics IntraProstatic Drug Elution (IPDE) therapy for prostate cancer.
No takes yet. Share an insight, caveat, or question.
Elaine Harris (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: